Skip to main content
. Author manuscript; available in PMC: 2008 Jan 16.
Published in final edited form as: Cancer Gene Ther. 2006 Oct 6;14(1):105–116. doi: 10.1038/sj.cgt.7700991

Figure 4.

Figure 4

Tissue and tumor specificity of the VEGF promoter in the adenoviral context. Mice received 1 × × 109 PFU of Ad5VEGFLuc or Ad5CMVLuc via tail vein injection (three per group). At 2 days after virus injection, mice were killed to obtain the organ samples. Each organ lysate was asayed for luciferase activity and normalized for protein concentration. Mean + s.e. of triplicate determination is shown. Tumors were induced by injection of 1 × 107 H157 cells on nude mice subcutaneously. When tumor formation was confirmed (6–8 mm in diameter), Ad5VEGFLuc (1 × 108 PFU) or Ad5CMVLuc (1 × 108 PFU) were injected into the tumor. Measurement of luciferase activity in tumor was performed same as above.